BioCentury
ARTICLE | Company News

Alexion acquires Wilson, adds late-stage asset

April 11, 2018 7:15 PM UTC

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) is acquiring Wilson Therapeutics AB (SSE:WTX) for SEK232 per share in cash, or about SEK7.1 billion ($848 million). The price represents a 70% premium to Wilson's Tuesday close of SEK136.20, before the deal was announced.

The deal gives Alexion Decuprate bis-choline tetrathiomolybdate (WTX101), a second-generation analog of ammonium tetrathiomolybdate in Phase III testing to treat Wilson's disease. Wilson Therapeutics said data are due in 2H19. Alexion spokesperson Kim Diamond told BioCentury while Wilson has done preclinical studies of WTX101 in other indications, Alexion plans to focus on treating Wilson's disease...